pharma xp consulting ltd
pharma xp consulting ltd Company Information
Company Number
08862562
Next Accounts
Oct 2025
Directors
Shareholders
christian seiler
justine stansall-seiler
Group Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
billingscroft 2 farquhar street, hertford, SG14 3BP
pharma xp consulting ltd Estimated Valuation
Pomanda estimates the enterprise value of PHARMA XP CONSULTING LTD at £86.3k based on a Turnover of £80.7k and 1.07x industry multiple (adjusted for size and gross margin).
pharma xp consulting ltd Estimated Valuation
Pomanda estimates the enterprise value of PHARMA XP CONSULTING LTD at £0 based on an EBITDA of £-87 and a 4.58x industry multiple (adjusted for size and gross margin).
pharma xp consulting ltd Estimated Valuation
Pomanda estimates the enterprise value of PHARMA XP CONSULTING LTD at £20.3k based on Net Assets of £11.6k and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharma Xp Consulting Ltd Overview
Pharma Xp Consulting Ltd is a live company located in hertford, SG14 3BP with a Companies House number of 08862562. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in January 2014, it's largest shareholder is christian seiler with a 80% stake. Pharma Xp Consulting Ltd is a established, micro sized company, Pomanda has estimated its turnover at £80.7k with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pharma Xp Consulting Ltd Health Check
Pomanda's financial health check has awarded Pharma Xp Consulting Ltd a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
2 Strong
1 Regular
5 Weak
Size
annual sales of £80.7k, make it smaller than the average company (£36.9m)
- Pharma Xp Consulting Ltd
£36.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 664%, show it is growing at a faster rate (5.5%)
- Pharma Xp Consulting Ltd
5.5% - Industry AVG
Production
with a gross margin of 20.4%, this company has a higher cost of product (36.8%)
- Pharma Xp Consulting Ltd
36.8% - Industry AVG
Profitability
an operating margin of -0.1% make it less profitable than the average company (7.3%)
- Pharma Xp Consulting Ltd
7.3% - Industry AVG
Employees
with 1 employees, this is below the industry average (106)
1 - Pharma Xp Consulting Ltd
106 - Industry AVG
Pay Structure
on an average salary of £63.7k, the company has an equivalent pay structure (£63.7k)
- Pharma Xp Consulting Ltd
£63.7k - Industry AVG
Efficiency
resulting in sales per employee of £80.7k, this is less efficient (£427.9k)
- Pharma Xp Consulting Ltd
£427.9k - Industry AVG
Debtor Days
it gets paid by customers after 7 days, this is earlier than average (62 days)
- Pharma Xp Consulting Ltd
62 days - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Pharma Xp Consulting Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pharma Xp Consulting Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Pharma Xp Consulting Ltd
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Pharma Xp Consulting Ltd
- - Industry AVG
PHARMA XP CONSULTING LTD financials
Pharma Xp Consulting Ltd's latest turnover from January 2024 is estimated at £80.7 thousand and the company has net assets of £11.6 thousand. According to their latest financial statements, Pharma Xp Consulting Ltd has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 443 | 210 | 181 | 250 | 370 | 250 | ||||
| Other Income Or Grants | ||||||||||
| Cost Of Sales | ||||||||||
| Gross Profit | ||||||||||
| Admin Expenses | ||||||||||
| Operating Profit | ||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Pre-Tax Profit | -34 | -8 | -159 | -273 | -20 | -817 | ||||
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Profit After Tax | -34 | -8 | -159 | -273 | -20 | -817 | ||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Retained Profit | -34 | -8 | -159 | -273 | -20 | -817 | ||||
| Employee Costs | 0 | 0 | ||||||||
| Number Of Employees | 1 | 1 | 1 | 1 | 1 | |||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 231 | 463 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 10,000 | 10,000 | 10,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 10,000 | 10,000 | 10,000 | 0 | 0 | 0 | 0 | 231 | 463 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 1,604 | 1,691 | 1,725 | 1,733 | 1,892 | 2,165 | 2,184 | 64,729 | 53,107 | 86,728 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1,604 | 1,691 | 1,725 | 1,733 | 1,892 | 2,165 | 2,184 | 64,729 | 53,107 | 86,728 |
| total assets | 11,604 | 11,691 | 11,725 | 1,733 | 1,892 | 2,165 | 2,184 | 64,960 | 53,570 | 86,728 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,640 | 23,474 | 30,578 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,640 | 23,474 | 30,578 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,640 | 23,474 | 30,578 |
| net assets | 11,604 | 11,691 | 11,725 | 1,733 | 1,892 | 2,165 | 2,184 | 50,320 | 30,096 | 56,150 |
| total shareholders funds | 11,604 | 11,691 | 11,725 | 1,733 | 1,892 | 2,165 | 2,184 | 50,320 | 30,096 | 56,150 |
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 | Jan 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Profit | ||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 231 | 0 | ||
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -87 | -34 | -8 | -159 | -273 | -19 | -62,545 | 11,622 | -33,621 | 86,728 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | -14,640 | -8,834 | -7,104 | 30,578 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||||
| Investing Activities | ||||||||||
| capital expenditure | ||||||||||
| Change in Investments | 0 | 0 | 10,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||
| Financing Activities | ||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| cash flow from financing | 0 | 10,000 | 0 | 0 | 1 | -47,319 | ||||
| cash and cash equivalents | ||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
pharma xp consulting ltd Credit Report and Business Information
Pharma Xp Consulting Ltd Competitor Analysis
Perform a competitor analysis for pharma xp consulting ltd by selecting its closest rivals, whether from the MANUFACTURING sector, other micro companies, companies in SG14 area or any other competitors across 12 key performance metrics.
pharma xp consulting ltd Ownership
PHARMA XP CONSULTING LTD group structure
Pharma Xp Consulting Ltd has no subsidiary companies.
Ultimate parent company
PHARMA XP CONSULTING LTD
08862562
pharma xp consulting ltd directors
Pharma Xp Consulting Ltd currently has 1 director, Dr Christian Seiler serving since Jan 2014.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Christian Seiler | United Kingdom | 54 years | Jan 2014 | - | Director |
P&L
January 2024turnover
80.7k
+18106%
operating profit
-87
0%
gross margin
20.5%
+0.95%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
January 2024net assets
11.6k
-0.01%
total assets
11.6k
-0.01%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
pharma xp consulting ltd company details
company number
08862562
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
January 2014
age
11
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
January 2024
previous names
N/A
accountant
-
auditor
-
address
billingscroft 2 farquhar street, hertford, SG14 3BP
Bank
-
Legal Advisor
-
pharma xp consulting ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pharma xp consulting ltd.
pharma xp consulting ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHARMA XP CONSULTING LTD. This can take several minutes, an email will notify you when this has completed.
pharma xp consulting ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
